Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database

García, Montserrat; Aranburu, Maite; Palacios–Zabalza, Itziar; Lertxundi, Unax; Aguirre, C

doi:10.1111/jcpt.12397

Cited by 87 publications

(103 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3132] Nevertheless, lymphopenia with saxagliptin (prescribing information) and higher potential of skin reaction observed with vildagliptin may theoretically suggest in favor of selective DPP-4 inhibition. [33]…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of teneligliptin

Singh

2017

Indian J Endocr Metab

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of teneligliptin

Singh

2017

Indian J Endocr Metab

View full text Add to dashboard Cite

“…5,6 The ROR was especially high for vildagliptin relative to other DPP4-I. Some studies using pharmacovigilance databases have demonstrated a significant association between intake of DPP4-I and BP onset in diabetic patients.…”

Section: Discussionmentioning

confidence: 99%

“…1 It has been reported that the onset of BP may be associated with the use of various drugs, such as antibiotics, antihypertensive drugs, anti-inflammatory drugs, diuretics, biopharmaceuticals, antirheumatic drugs and vaccines. [3][4][5][6][7] Most recently, an inhomogeneity analysis of BP associated with the use of DPP4-I based on the Japanese Adverse Drug Event Report database (JADER) 8 was also reported. [3][4][5][6][7] Most recently, an inhomogeneity analysis of BP associated with the use of DPP4-I based on the Japanese Adverse Drug Event Report database (JADER) 8 was also reported.…”

Section: Introductionmentioning

confidence: 99%

Analysis of patients with drug‐induced pemphigoid using the Japanese Adverse Drug Event Report database

Tanaka

Ishii

2018

The Journal of Dermatology

View full text Add to dashboard Cite

To clarify the incidence of drug‐induced pemphigoid in Japan, we conducted a database search and analysis using the Japanese Adverse Drug Event Report database (JADER). Among the cases recorded in JADER between April 2004 and November 2017, we targeted “pemphigoid” and analyzed the patients’ backgrounds, drug involvement, time of pemphigoid onset, outcomes and year reported. For cases where three or more drugs were reportedly involved, the signal index was calculated using the reporting odds ratio (ROR) method. The total number of reported pemphigoid cases was 769. Males accounted for 58% (446 cases) and patients over the age of 60 years accounted for 82% (630 cases). The most frequently reported causative drug was vildagliptin (288 cases), followed in order by sitagliptin phosphate hydrate (102 cases), teneligliptin hydrobromide hydrate (86 cases), linagliptin (64 cases) and furosemide (46 cases). For the 27 causative drugs, the safety signal was detected by the ROR method. The median time to onset tended to be long for these drugs. For vildagliptin with the largest reported number, the value was 508 days (range, 2–1871). Analysis of outcomes demonstrated recovery or improvement in 66.3% of cases. Analysis of the years in which reports had been published revealed that the number of pemphigoid cases has increased rapidly in recent years. Our survey was able to reveal useful data on the incidence of drug‐induced pemphigoid. We expect that these results will aid the early detection and treatment of this condition.

show abstract

“…[2][3][4][5][6] A large-scale analysis of BP induced by DPP-4 inhibitors was performed using the European pharmacovigilance database. 7 According to the data, the proportional reporting ratio for linagliptin and BP was the second highest after that for vildagliptin. However, it has not previously been reported that the mucous membranes are severely affected in patients using DPP-4 inhibitors including linagliptin.…”

mentioning

confidence: 97%

Linagliptin treatment‐associated bullous pemphigoid presenting severe mucosal erosions

Mukaijo

Kanaoka

Kawano

et al. 2018

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

It was recently reported that some cases of bullous pemphigoid (BP) were induced by dipeptidyl peptidase (DPP)-4 inhibitors used for the treatment of type 2 diabetes mellitus. We present a case of BP with severe esophageal mucosal erosions occurring during linagliptin administration.A 64-year-old man with diabetes mellitus was referred to our department complaining of a diffuse eruption of bullae and erosions

show abstract

Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database

Abstract: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.

Cited by 87 publications

References 6 publications

Efficacy and safety of teneligliptin

Efficacy and safety of teneligliptin

Analysis of patients with drug‐induced pemphigoid using the Japanese Adverse Drug Event Report database

Linagliptin treatment‐associated bullous pemphigoid presenting severe mucosal erosions

Contact Info

Product

Resources

About